Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Operating margin

Operating margin at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-982.4%-1,538pp
Arvinas logo
ArvinasARVN
-283.8%-310pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-333.5%-114pp
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-5,266.4%-9,520pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-242%—
Janux Therapeutics logo
Janux TherapeuticsJANX
-598.1%-296pp

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Net margin-560.8%—
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

operating income/total revenue=-633%

Based on trailing twelve months.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711

FAQ

What is Monte Rosa Therapeutics, Inc.'s operating margin?
Monte Rosa Therapeutics, Inc. (GLUE) reported operating margin of -633% in Q2 2026.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.

Ask your AI about Monte Rosa Therapeutics, Inc.'s operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude